# EDGAR Filing Document

**Accession Number:** 0001931356
**File Stem:** 0001931356-26-000013
**Filing Date:** 2026-3
**Character Count:** 10552
**Document Hash:** b60dd7ab81ba7526dd8b62c94171aaf2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001931356-26-000013.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001931356-26-000013

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tempest Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001544227
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451472564
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87213
- **FILM NUMBER:** 26793663

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY
- **STREET 2:** SUITE 400
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 415-798-8589

**MAIL ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY
- **STREET 2:** SUITE 400
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Millendo Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20181207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OvaScience, Inc.
- **DATE OF NAME CHANGE:** 20120308
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Angel Matthew
- **CENTRAL INDEX KEY:** 0001931356

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 160-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**TEMPEST THERAPEUTICS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Matthew Angel**<br>c/o Tempest Therapeutics, Inc.<br>2000 Sierra Point Parkway, Suite 400<br>Brisbane CA 94005<br>(415) 798-8589

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/24/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Matthew Angel** | Name of reporting person<br>**Matthew Angel** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**5531516.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**5531516.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5531516.00** | Aggregate amount beneficially owned by each reporting person<br>**5531516.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**37.4%** | Percent of class represented by amount in Row (11)<br>**37.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
TEMPEST THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA, 94005

This Amendment No. 1 to Schedule 13D ("Amendment No. 1") is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.0001 per share of Tempest Therapeutics, a Delaware corporation, as filed with the Securities and Exchange Commission (the "SEC") on February 10, 2026 (the "Initial Schedule 13D"). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Initial Schedule 13D. The Initial Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Initial Schedule 13D remains in full force and effect.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, the Reporting Person beneficially owns an aggregate of 5,531,516 shares of Common Stock.

The Reporting Person may be deemed to beneficially own 37.4% of the Issuer's outstanding Common Stock which is calculated based upon 14,344,334 shares of Common Stock outstanding immediately following the close of the transactions contemplated by the Purchase Agreement on March 24, 2026.

**(b)**
The Reporting Person has sole voting and dispositive power over 5,531,5164 shares of the Issuer's Common Stock.

**(c)**
Except as described herein, the Reporting Person has not purchased or sold any shares of Common Stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Asset Purchase Agreement

On November 19, 2025, the Issuer executed the Asset Purchase Agreement with Sellers, pursuant to which 8,268,495 shares of Common Stock were issued to Erigen on behalf of both Sellers. Pursuant to the Asset Purchase Agreement, the Issuer has agreed to, within thirty (30) days of the Closing, prepare and file with the SEC a registration statement on Form S-1 or such other form under the Securities Act that may then be available (the "Registration Statement"), with respect to the resale of the Issuer Common Stock issued to Erigen pursuant to the Asset Purchase Agreement. The Issuer shall use reasonable best efforts to have the Registration Statement declared effective by the SEC as promptly as reasonably practicable and shall use reasonable best efforts to keep the Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by Erigen or its equityholders (collectively, the "Holders") of the Common Stock covered thereby until such time as (i) all securities covered by the Registration Statement have been resold or (ii) the securities may be resold by the Holders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 promulgated under the Securities Act of 1933, as amended.

Lock-up Agreement

Concurrently with the execution of the Asset Purchase Agreement, Erigen entered into a lock-up agreement with the Issuer (the "Lock-Up Agreement") pursuant to which, subject to specified exceptions, Erigen, on behalf of itself and its permitted transferees, has agreed not to transfer 50% of its shares of Issuer Common Stock for the period commencing upon the Closing and ending 180 days after the date of Closing.

Employment Agreement

In connection with his appointment as President and Chief Executive Officer of the Issuer, Dr. Angel entered into an employment agreement with the Issuer (the "Angel Employment Agreement"), effective as of February 3, 2026. A summary of the key terms of the Angel Employment Agreement is contained in the Company's current Report on Form 8-K filed with the SEC on February 6, 2026.

Security Purchase Agreement

On March 20, 2026, the Issuer entered into the Purchase Agreement with Investors, pursuant to which the Issuer agreed to issue and sell in a private placement (the "Private Placement") an aggregate of 462,964 shares of the Issuer's Common Stock, and, in lieu of Common Stock, pre-funded warrants to purchase up to 462,963 shares of Common Stock, in each case accompanied by (i) Series A Warrants to purchase up to 925,927 shares of Common Stock  and (ii) Series B Warrants to purchase up to 925,927 shares of Common Stock.

The Purchase Agreement contains customary representations, warranties and agreements by the Issuer, customary conditions to closing, indemnification obligations of the Issuer, including for liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

Registration Rights Agreement

On March 20, 2026, the Issuer also entered into a registration rights agreement with the Investors (the "Registration Rights Agreement"), pursuant to which the Issuer agreed to file registration statements under the Securities Act, with the SEC, covering the resale of the Common Stock to be issued in the Private Placement and the shares of Common Stock underlying the Common Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a "full review" by the SEC.

Common Warrant

On March 24, 2026, the Issuer issued Factor a Series A Warrant to purchase 231,482 shares of Common Stock and Series B Warrant to purchase 231,482 shares of Common Stock.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Matthew Angel

**Signature:** /s/ Matthew Angel

**Name/Title:** Matthew Angel

**Date:** 02/25/2026